CR20160061A - Formulación estable líquida de etelcalcetide (amg 461) - Google Patents

Formulación estable líquida de etelcalcetide (amg 461)

Info

Publication number
CR20160061A
CR20160061A CR20160061A CR20160061A CR20160061A CR 20160061 A CR20160061 A CR 20160061A CR 20160061 A CR20160061 A CR 20160061A CR 20160061 A CR20160061 A CR 20160061A CR 20160061 A CR20160061 A CR 20160061A
Authority
CR
Costa Rica
Prior art keywords
etelcalcetide
amg
stable formulation
formulation liquid
liquid
Prior art date
Application number
CR20160061A
Other languages
English (en)
Inventor
Derek Maclean
Qun Yin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51213030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20160061(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20160061A publication Critical patent/CR20160061A/es

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04D—NON-POSITIVE-DISPLACEMENT PUMPS
    • F04D25/00—Pumping installations or systems
    • F04D25/02—Units comprising pumps and their driving means
    • F04D25/06—Units comprising pumps and their driving means the pump being electrically driven
    • F04D25/0606—Units comprising pumps and their driving means the pump being electrically driven the electric motor being specially adapted for integration in the pump
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01D—NON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
    • F01D15/00—Adaptations of machines or engines for special use; Combinations of engines with devices driven thereby
    • F01D15/10—Adaptations for driving, or combinations with, electric generators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan una formulación líquida que comprende un agonista péptido del receptor que detecta calcio y un método para preparar y usar la formulación.
CR20160061A 2013-06-28 2014-06-27 Formulación estable líquida de etelcalcetide (amg 461) CR20160061A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840618P 2013-06-28 2013-06-28
PCT/US2014/044622 WO2014210489A1 (en) 2013-06-28 2014-06-27 Stable liquid formulation of amg 416 (velcalcetide)

Publications (1)

Publication Number Publication Date
CR20160061A true CR20160061A (es) 2016-09-28

Family

ID=51213030

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20160002A CR20160002A (es) 2013-06-28 2014-06-27 Formulación estable líquida de etelcalcetide (amg 461)
CR20160061A CR20160061A (es) 2013-06-28 2014-06-27 Formulación estable líquida de etelcalcetide (amg 461)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20160002A CR20160002A (es) 2013-06-28 2014-06-27 Formulación estable líquida de etelcalcetide (amg 461)

Country Status (38)

Country Link
US (4) US9820938B2 (es)
EP (3) EP3878433A1 (es)
JP (1) JP6027708B2 (es)
KR (1) KR102231957B1 (es)
CN (2) CN114376970A (es)
AP (1) AP2015008936A0 (es)
AR (1) AR096773A1 (es)
AU (1) AU2014302122B2 (es)
CA (1) CA2916222C (es)
CL (1) CL2015003738A1 (es)
CR (2) CR20160002A (es)
CY (1) CY1120811T1 (es)
DK (1) DK3013318T3 (es)
EA (1) EA030220B1 (es)
ES (1) ES2633989T3 (es)
HR (1) HRP20171092T1 (es)
HU (1) HUE034209T2 (es)
IL (1) IL243210B (es)
JO (1) JO3817B1 (es)
LT (1) LT3013318T (es)
MA (1) MA38724B1 (es)
ME (1) ME02818B (es)
MX (1) MX2015017952A (es)
MY (1) MY180276A (es)
PE (2) PE20160549A1 (es)
PH (1) PH12015502816B1 (es)
PL (1) PL3013318T3 (es)
PT (1) PT3013318T (es)
RS (1) RS56238B1 (es)
SG (1) SG11201510647TA (es)
SI (1) SI3013318T1 (es)
SM (1) SMT201700401T1 (es)
TN (1) TN2015000569A1 (es)
TW (1) TWI635874B (es)
UA (1) UA115373C2 (es)
UY (1) UY35636A (es)
WO (1) WO2014210489A1 (es)
ZA (1) ZA201600238B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160549A1 (es) 2013-06-28 2016-06-15 Amgen Inc Formulacion liquida estable de etelcalcetida (amg 416)
WO2015154031A1 (en) 2014-04-03 2015-10-08 Amgen Inc. Method for preparing amg 416
JP6783787B2 (ja) * 2015-03-26 2020-11-11 アムジェン インコーポレイテッド エテルカルセチドの調製のための液相方法
CN106137979A (zh) * 2015-03-31 2016-11-23 深圳翰宇药业股份有限公司 一种冻干粉针剂及其制备方法
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928320B (zh) * 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN110054662B (zh) * 2018-01-18 2021-03-02 成都圣诺生物制药有限公司 一种固相合成Etelcalcetide的方法
WO2021231960A1 (en) 2020-05-15 2021-11-18 Amgen Inc. Methods of treating left ventricle hypertrophy
CN111925415A (zh) * 2020-08-10 2020-11-13 海南中和药业股份有限公司 一种维拉卡肽杂质的制备方法
WO2022034545A1 (en) * 2020-08-14 2022-02-17 Aurobindo Pharma Limited Etelcalcetide formulations for parenteral use
MX2023013066A (es) * 2021-05-06 2023-11-15 Amgen Inc Formulaciones de etelcalcetida.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365712B1 (en) 1996-10-25 2002-04-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 α subunit
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
AU2004243531B2 (en) 2003-06-03 2009-11-05 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
KR101308912B1 (ko) * 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
JP5645408B2 (ja) * 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
US8067532B2 (en) * 2007-01-19 2011-11-29 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
EP2264138B2 (en) 2009-06-19 2023-03-08 The Procter & Gamble Company Liquid hand dishwashing detergent composition
EP2459208B1 (en) * 2009-07-29 2016-09-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
WO2012075375A1 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
PT2717896T (pt) 2011-06-08 2016-12-23 Kai Pharmaceuticals Inc Agentes terapêuticos para a regulação do fósforo sérico
MX355063B (es) 2011-11-10 2018-04-04 Kai Pharmaceuticals Inc Calcimiméticos y métodos para su uso.
PE20160549A1 (es) 2013-06-28 2016-06-15 Amgen Inc Formulacion liquida estable de etelcalcetida (amg 416)
WO2015154031A1 (en) * 2014-04-03 2015-10-08 Amgen Inc. Method for preparing amg 416

Also Published As

Publication number Publication date
HK1222557A1 (en) 2017-07-07
EP3246017A1 (en) 2017-11-22
EP3878433A1 (en) 2021-09-15
UY35636A (es) 2015-01-30
TWI635874B (zh) 2018-09-21
AR096773A1 (es) 2016-02-03
EP3246017B1 (en) 2021-03-24
PE20210413A1 (es) 2021-03-04
HRP20171092T1 (hr) 2017-10-06
DK3013318T3 (en) 2017-08-07
EA030220B1 (ru) 2018-07-31
RS56238B1 (sr) 2017-11-30
SG11201510647TA (en) 2016-01-28
US20180080452A1 (en) 2018-03-22
MA38724B1 (fr) 2017-11-30
US20190285074A1 (en) 2019-09-19
LT3013318T (lt) 2017-09-11
PH12015502816A1 (en) 2016-03-21
KR20160043954A (ko) 2016-04-22
CY1120811T1 (el) 2019-12-11
HUE034209T2 (en) 2018-02-28
NZ715403A (en) 2020-10-30
US11162500B2 (en) 2021-11-02
SI3013318T1 (sl) 2017-11-30
ZA201600238B (en) 2017-05-31
BR112015032615A2 (pt) 2017-07-25
US9820938B2 (en) 2017-11-21
TW201542239A (zh) 2015-11-16
US10344765B2 (en) 2019-07-09
JO3817B1 (ar) 2021-01-31
PL3013318T3 (pl) 2018-03-30
JP2016523916A (ja) 2016-08-12
CA2916222C (en) 2021-05-18
MY180276A (en) 2020-11-26
CN114376970A (zh) 2022-04-22
PT3013318T (pt) 2017-07-24
PH12015502816B1 (en) 2016-03-21
JP6027708B2 (ja) 2016-11-16
KR102231957B1 (ko) 2021-03-25
ME02818B (me) 2018-01-20
MA38724A1 (fr) 2017-03-31
AP2015008936A0 (en) 2015-12-31
SMT201700401T1 (it) 2017-09-07
TN2015000569A1 (en) 2017-04-06
US20160220486A1 (en) 2016-08-04
US11959486B2 (en) 2024-04-16
CR20160002A (es) 2018-02-13
CL2015003738A1 (es) 2016-12-09
US20220042515A1 (en) 2022-02-10
CA2916222A1 (en) 2014-12-31
EP3013318B1 (en) 2017-04-19
CN105764487A (zh) 2016-07-13
WO2014210489A1 (en) 2014-12-31
UA115373C2 (uk) 2017-10-25
AU2014302122B2 (en) 2018-12-06
IL243210B (en) 2020-02-27
MX2015017952A (es) 2016-10-28
EA201690099A1 (ru) 2016-06-30
ES2633989T3 (es) 2017-09-26
PE20160549A1 (es) 2016-06-15
AU2014302122A1 (en) 2016-01-21
IL243210A0 (en) 2016-02-29
EP3013318A1 (en) 2016-05-04

Similar Documents

Publication Publication Date Title
CR20160002A (es) Formulación estable líquida de etelcalcetide (amg 461)
CL2017000654A1 (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CR20160141A (es) Formulaciones de anticuerpos anti-pdl1
CL2016001586A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
MX2016007576A (es) Anticuerpos e inmunoconjugados anti-cd33.
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2018003045A1 (es) Semaglutida en afecciones cardiovasculares.
LT3684813T (lt) Agonistiniai cd40 antikūnai
BR112017004745A2 (pt) adição a um aplicador médico
UY35750A (es) Moduladores octahidro-ciclopenta[c] pirrol negativos de nr2b
CO2017007316A2 (es) Formulación farmacéutica
IL268044B1 (en) Syringe adapter
EP3551657A4 (en) CHIMERIC CHLOROTOXIN RECEPTORS
UY35751A (es) Moduladores negativos de n-arilmetilo sulfonamida de nr2a
CO7160067A2 (es) Formulaciones de agonistas del receptor de somatostatina
UY35823A (es) Profármacos de antagonista de nmda
UA116372C2 (uk) Частинки резинату фенілефрину
MX382918B (es) Proceso para fabricar partículas de resinato de fenilefrina; partículas de resinato de fenilefrina y uso de las partículas de resinato de fenilefrina en formulaciones farmacéuticas.
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
MX2015012542A (es) Partículas de resinato de fenilefrina y su uso en formulaciones para productos farmacéuticos.
UA107534U (uk) Застосування вінборону для потенціювання аналгетичного ефекту ібупрофену